• Newsroom
  • Join us!
  • Newsletter
  • Kontakt
  • English English English en
  • Deutsch Deutsch German de
Experts Institut
  • Business Consulting
    • Business Solutions
      • Digitization
      • Sustainability Corporate strategy
      • Management systems
      • Project management
      • Strategy & Performance
      • Transformation & Leadership
  • GXP Consulting
    • GMP Beratung
      • Audits & inspections
      • GMP/GXP training courses
      • GMP Aircheck4
      • Continuous Manufacturing
  • Industries
    • Pharma
    • Service providers & trade
    • Automotive
    • FOOD & BEVERAGES
    • Financial service providers & insurances
    • Informationstechnik (IT)
    • Aerospace
  • Academy
    • Individuelle Inhouse-Schulungen
      • GMP/GXP training courses
    • Experts Institut Events
      • Academy
    • Direkt buchen
      • Live-Events
      • On-Demand Webinar
  • Kunden
  • Über uns
    • Über uns
      • Guideline
      • Portrait
      • Team
      • Geschäftsführung
      • Vision
      • Events
      • History Experts Institute
      • Sustainability at the Experts Institute
      • Social responsibility
    • Wissen
      • GMP Glossary
      • FAQ – Frequently asked questions in the GMP environment
      • Videos
    • Blog
      • Newsroom
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
  • Link to LinkedIn
  • Link to Xing
GMP, GXP, News

GMP and Digitalization: Some basic thoughts

It is almost 8.00 am, we are standing on front of a building which houses an officially GMP-accredited contract laboratory service. Our task for today: carry out a full blown GMP-audit on the contract lab.

On the inside I am a bit excited. Because I know that in each audit I do not only evaluate others, but I will also gain and learn! And each auditee – be it a laboratory, a GMP-manufacturer or a material supplier (API, excipients, packaging materials) is different, and each uses different ways and systems to implement GMP. So far so good.

Later that day the audit is over and my co-auditor and I we feel overall happy with the audit. Still – we also feel disillusioned: we had expected a more modern way of raw data, data and document management. What did we find? An almost 100% paper-based GMP- and data management system, with all its nicks and dents when it comes to the GMP such a system can provide – it is alright, but it no doubt has limits.

Fully paper-based – that something like this still exists? And that in a GMP-bound establishment? It sure does still exist.

In the GMP-Universe the Digitization Truck has departed, but by far not delivered to all yet!

In our line of work at Experts Institut, we are often surprised by how many companies in the drug manufacturing, medical device, and cosmetic GMP areas operate with a very low degree of digitalization in their processes and data management. This observation grounds everyone and reminds us that digitization is not as advanced in the regulated industry as we might like to believe. Despite being a socio-economic and political desire among regulators and industry, progress is still lacking. In fact though, it is not(!) a given, it is not a self-propagating realization all over the place. And this does not only concern small companies who seem to just not be able to finance the digital transformation. It also concerns for example medium-size GxP-entities. If You think that the size of a company is an indicator for its degree of digitalization then You need to think again. There is no such connection. You’d be surprised what we encounter in our daily work.

Even politics, cultural Western optimism and the strong drive to achieve and constantly change towards something new is not always the recipe for producing a digital revolution by and large.

Incentives for change must come from the market, it must be attractive, plausible to implement and at reasonable cost. And in a highly regulated area like the white industry(Pharmaceutical GMP, Medical Device Quality Assurance, Cosmetic-Industry) New means not only Opportunity, but also Risk. And in white industry products the risk is considerable. An excellent example is the timidity of the GxP-industry to enter continuous manufacturing transformation – for a lack of experience with the regulators in this area. A similar reason may be at the root of the spotty coverage of digitalization.

Concerns and Opportunities of Digitalization for GxP Establishments

Some companies shy away from larger transformations due to finances thin-stretched. And due to a blurred understanding where then the actual benefit of digital data- and process-management really hit home positively.

Others simply do not see any need to change and keep up with modernization. Because for a period of time resisting change can go without noticing any consequences in the business numbers and balances. Even in terms of basic GMP-systems quite a few companies are chronically underfinanced.

Again others are apprehensive about the risk that may come to their data and company information due to migrating everything into electronic formats, networks and clouds – and that is a very understandable risk. There are solutions to protect data from even the most sphisticated attacks, but they will cost.

Looking at the opportunities: once digitalization has reached a company’s operational processes – where product is actually made (not just where warehousing and document management are electronic) – a company has arrived on a temporary plateau of readiness for tomorrow.

And here is the thing: that readiness will likely make or break any business eventually – but most certainly a GMP-business!

You will need digitalized company processes (manufacturing, analytics, logistics, quality management, compliance, engineering and technical systems) and data management to be ready for:

  • a globalized approach in making business wich data, knowledge and information sharing at the top (regulatory submission, block chain approaches for decentralized data management),
  • adapting to constantly advancing regulatory standards for GMP-data management and managing modern technologies in development and even in routine production (see for examples EU GMP Guide Annex 1),
  • the time when advanced and continuous manufacturing becomes more and more established (and this is already happening),
  • advancing cost efficiency concerning staff Your system would otherwise require to cater to the massive burden of GMP-/GxP-requirements.

Where to start? And how to get on the truck?

Digitalization in a GMP-/ GxP-liable company typically follows some sort of evolutionary model.

  1. Basic for any company is to have at least material management systems, warehousing and logistics managed by electronic systems. At least for article data and inventory as well as location and status management such systems are standard. This is nothing new of course. But I tell You: there are in fact some companies that don’t even have that.
  2. The second layer is often electronic Document Management (eDMS).
  3. Then comes electronic batch record – at least partially, more often electronic deviation and change management or other QM subsystems – mostly non-integrated but separate applications.
  4. and then – typically – a full electronic Quality Management System, some commpanies using the opportunitydigitizing their business and administrative processes if they haven’t so yet.
  5. Global companies need to deal with additional issues with data sharing and data security across the corporation, leading to for example decentralized data storage solutions for example controlled via block chain technology.
  6. And by the latest at that point comes the phase of trying to integrate all of this.
Basic Evolutionary Degress of Digitalization in GMP and GxP-liable Companies (pharmaceutical manufacturing and on-coming suppliers, medical devices industry, cosmetics).

As You can see: if Your company is currently a low-digitized business – do not be dismayed. You may have just about missed out all those years where all the others have hustled and bustled to add one little digital island system after the other. And You now have the advantage to look back on this and make a decision to roll out digitalization compreheneively and for the first time!

Digitalization in a GMP-Environment

There are challenges of course. Digitalization cannot be rushed or it will result in a gigantic failure with data loss, loss of company spirit and – worst case – of good people who will quit over the frustration of the failed digitalization effort. Leadership will lose credibility and trust – which is worse than anything from a company perspective.

The more integrated You advance Your digitalization the more keeping in with the validated state is a true GMP-challenge. And a huge caveat I must place here is: Be very thorough when working with validation-packages from software suppliers! They come from a non-GMP quality system environment. Often no QMS around the software development at all. And so You need to take charge of what is done concerning validation (initial, updates, integration and post-integration management) – even and especially when it is an ISPE GAMP®5 category 3 or category 4 system. And do not mistake brand names for assurance of GMP-compliance. Our audit practice shows that even systems which are heavily advertized for can lack basic regulatory compliance requirements or are not fully compatible with local national GxP-requirements. (An issue that even electronic deviation workflows or eBR systems can have).

For some newer technologies (Blockchain Technology, Decentralized Data Management, AI / Machine Learning / Neuronal Networks) You must understand: regulatory agencies are yet to say and to judge what they require from the GxP-viewpoint, depending on each situation of digital integrated process landscaping and data generation and management. Of course You can apply the current GxP-regulations’ point to now. But it may not in all cases be what You need.

And take a good look where You will market Your products: some regulatory agencies are on high alert concerning data and processes in digitalized environments and close to publishing guidance, others are – yet – fast asleep but won’t be forever.

What We (EI) do when We support a company in digitalization or digital transformation?

We Support Your planning – Organization and Required Efforts:

  • Feasibility study, digitalization concept, regularoy GMP-/GxP- and cGMP compliance assessment, also of existing levels of digitalization.

EI prepares Your body of documents:

  • With You we estalish and review the required GxP-relevant document You will need for individual systems and for global structure concept papers and policies keeping in with Your data integrity and data security requirements.

We work with those from Your company who will live and operate the / in the system:

  • Coordinating a digitalization project can be challenging and requires a sober and coordinative mind and management skills. Often companies new in the arena of digitalization do not have personnel to carry such a project and coordinate all the stakeholders – on top of their daily workload. But we (EI) have people who can take such a mandate and help Your own people advance in knowledge and with the project alike.
  • We keep alliance with partners who can drive the actual digitalization of data. Especially if you find no suitable business counterpart for example doing power BI for data pooling structures and more.

What will it take Your company (with or without external help)?

If You do digitalization – especially if You take a larger step (no matter in what area in Your GMP-, GDP, or GxP-company), You might as well do it wholeheartedly.

  • It will take extra effort on the part of everyone involved, and this is a real extra – not just an imaginary thought. Prepare Your staff wisely! Communicate with credibility where this is going.
  • It will take a darn good project manager and project management structure that can react to the unforeseen.
  • It will take nerve – lots of nerve – to face how many things that used to be non-digitalized actually never really worked! This will cause delay.
  • It will take plausible timelines that are only to a limited degree tied to immediate business goals – for then if it (digitalization) delays or fails – then all fails!
  • And – most importantly – it will take a change agent to generate acceptance of the things that are coming.

All things considered: be courageous and give it a go. In the long run there will likely be no way around a rather comprehensive digitalization for GxP-companies. Now is a good time.

Get ahead and in touch with us – info@expertsinstitut.de

Read our full blog: https://experts-institut.de/newsroom/

And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

28. March 2024/by Dr. rer. nat. Dietmar Gross
https://experts-institut.com/wp-content/uploads/2024/03/1711610066872.png 720 1280 Dr. rer. nat. Dietmar Gross https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dr. rer. nat. Dietmar Gross2024-03-28 18:34:562024-10-29 07:59:27GMP and Digitalization: Some basic thoughts
News

Shaping the future: AI as the key to progressive corporate governance

Künstliche Intelligenz (KI)

Artificial intelligence (AI) is more than just a buzzword from the world of science fiction and robotics – it is a technology that is deeply integrated into our everyday lives. As a dynamic and progressive field, AI aims to develop systems that are capable of performing tasks previously reserved for the human mind. Whether it’s algorithms that learn from experience or systems that can understand and respond to human language, AI is opening up new horizons in technological development. It promises to fundamentally change the way we work and live by optimizing processes, creating innovative solutions and improving efficiency. In addition, AI enables more natural interaction between humans and machines through the development of intuitive user interfaces and voice assistants that make our everyday lives easier. With its ability to transform industries from medicine to manufacturing, AI has gone from a concept of the distant future to a present reality that is revolutionizing the business world across all sectors.

Technologischer Fortschritt

Experts Institut Beratungs GmbH recognized the transformative power of artificial intelligence at an early stage. Our commitment to the use of AI technology is aimed at optimizing our operations, overcoming real challenges and creating substantial added value. Our decision to integrate AI into the way we work is based on the conviction that technological progress should improve our lives and create more efficient and intelligent solutions.

KI-Technologie

The transition to AI technology not only marks a technological advance for us, but is also an expression of our commitment to customers and employees to create a better, more functional future. This strategic orientation is based on careful planning and a commitment to ethical principles and sustainability in dealing with AI.

At Experts Institute, we are more than a team – we are a community dedicated to making a positive impact on the future. Together, we want to explore the many possibilities that artificial intelligence opens up for us and thus pave the way to a promising future.

23. March 2024/by Dipl. Ing. Wolfgang Rudloff
https://experts-institut.com/wp-content/uploads/2023/11/DALL·E-2023-11-05-14.56.45-Refine-the-double-exposure-image-of-the-silhouette-of-a-Hispanic-man-with-themes-related-to-the-pharmaceutical-industry.-The-man-is-in-contemporary-bu.png 1024 1792 Dipl. Ing. Wolfgang Rudloff https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dipl. Ing. Wolfgang Rudloff2024-03-23 12:20:132024-03-23 12:25:54Shaping the future: AI as the key to progressive corporate governance
GMP

Annex 1 – Revolution in GMP heaven?

The new Annex 1

a document that is awaited with more excitement than ever before in the history of GMP regulations. One reason for this is that Annex 1 has now been available as a draft for more than 4 years and its publication has been repeatedly delayed for various reasons. According to current information, the publication is now scheduled for September 2022.

What is new and therefore very special?

On the one hand, the (recommended) scope of Annex 1 has been significantly expanded. In future, the focus will no longer be solely on the manufacture of sterile medicinal products, but it is recommended that “principles can also be used to support the manufacture of other products that are not intended to be sterile, such as certain liquids, creams, ointments and biological intermediates with low biological load”. It can therefore be assumed that the requirements, e.g. for the definitions of cleanroom zoning and the associated qualification and implementation of monitoring, will then also be applied to other production facilities that were not previously included in the Annex 1 control loop.

Monitoring of processes

The topic of monitoring processes, including the requirements for the expertise of all those involved in the value creation process, is then very much in focus and clear expectations are defined. For example, the specification of the bacterial load in the A zone changes from previously < 1 CFU/m³ air volume in the monitoring of room conditions to 0 CFU/m³ (“no growth”) with the expectation that every occurrence of a germ is immediately transferred to an investigation (deviation), with the requirement that the “real cause” is also determined. Annex 1 then formulates the requirement that the process control in the manufacture of sterile medicinal products is closely monitored, e.g. with the requirement of QA monitoring through windows in the cleanroom that allow a complete view of the processes, or alternatively by means of recording cameras.

The central theme in Annex 1

however, is the requirement to implement a so-called contamination control strategy (CCS) in the company, which, on the basis of a detailed risk analysis, determines the corresponding assessments of possible influencing factors for the occurrence of particulate or microbial contamination and defines the strategic measures for defense / monitoring. In the current reading of the new Annex1 , this is to be interpreted as meaning that, in addition to the SMF and VMP, a further strategy document should be created and maintained at a high level in the company’s organizational structure on the basis of a well-implemented risk management system.

Overall, Annex 1 has become much more technical. This is the first time that the media systems have been recorded in great detail and clear requirements for the design / definition of acceptance criteria have been formulated and specified.

APS (Aseptic Process Simulation)

A large part of the new Annex 1 is taken up by the actual production, including the chapter of the APS (Aseptic Process Simulation) formerly known as MediaFill. There are not necessarily any revolutionary changes, but there is a significantly greater specification of current practice combined with the requirements for the qualification of those involved and the targeted use of the risk management system.

Conclusion

Very exciting, very ambitious. With publication, it will be a major task in the company to evaluate the many clarifications / new requirements and changes, and to derive and implement the right conclusions with regard to implementation.

More information

Please contact us for further training and consulting services relating to Annex 1 via e-mail info@expertsinstitut.de

Target group

The online seminar is no longer only aimed at employees working with sterile medicinal products, but is open to the entire spectrum, i.e. everyone involved in the implementation / execution of Annex 1 in the company. Departments such as production, quality, QA / QC, as well as engineering, plant manufacturers and also inspectors benefit from the knowledge imparted in this seminar. Contact: info@expertsinstitut.de

Read our entire blog: https://experts-institut.de/newsroom/

And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

18. February 2023/0 Comments/by Dipl. Ing. Wolfgang Rudloff
https://experts-institut.com/wp-content/uploads/2023/10/Ludwig_A_photo_of_a_CEO_and_his_advisor_and_a_business_man_disc_a3dfa66c-c215-4a19-93d7-516a4de4c1e8.png 816 1456 Dipl. Ing. Wolfgang Rudloff https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dipl. Ing. Wolfgang Rudloff2023-02-18 17:18:092024-10-29 07:59:27Annex 1 – Revolution in GMP heaven?
GMP

EudraLex Vol. 4 Part IV: One for all?

Biotechnologically produced drugs are booming

Advanced therapy medicinal products (ATMPs) are at the forefront of regulatory developments, including good manufacturing practice requirements. A still very young ATMP GMP guide is going down paths that have not yet existed in the GMP universe.

GMP regulations – EudraLex

Firstly, the 90-page guide is largely independent of other GMP regulations. This is very surprising, as the annexes of the GMP Guide in particular have almost always been applied to all other pharmaceutical situations. However, there are hardly any references to the classic annexes in the ATMP guidelines.

Regulations Compliance

ATMP Guide

Secondly, the new ATMP Guide promotes a more risk-based approach in the pharmaceutical quality system. This may not sound new in principle, but in terms of conventional GMP requirements, it certainly is. If the Guide is interpreted literally, there are some degrees of freedom that historically did not exist for the manufacture of medicinal products or that were often not granted in practice despite ICHQ9 / GMP Guideline Part 3 – depending on the supervisory authority.

GMP special regulations

Thirdly, there are some special GMP regulations for ATMPs, such as decentralized release or concessions to process validation requirements. It is worth studying the text carefully, as much of it sounds similar to the familiar GMP regulations, but on closer inspection the details are different. And it adds up(!).

Finally, the ATMPs GMP guideline also sets out its own rules for investigational medicinal products. No wonder, because the IMP GMP Guide, which is also very new and is currently placed under EUDRALEX Volume 4 Annex 13, does not apply to I-ATMPs. In clinical development, this also means that it pays to take a closer look.

Conclusion

The latest ATMP guideline is not only a helpful tool for clarifying the regulatory expectations of GMP. But it also takes an important step away from a less rigid application of fixed and sometimes excessive specification lists (GMP overkill), towards an adapted GMP approach – namely quality assurance based on technical knowledge and compliance awareness.

It remains to be seen whether the European way of thinking will prove to be compatible with the requirements of other countries, or whether this fundamentally sensible EU approach will simply have to serve an additional compliance world that will not exist anywhere else in the world.

Read our entire blog: https://experts-institut.de/newsroom/
And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

18. February 2023/0 Comments/by Dipl. Ing. Wolfgang Rudloff
https://experts-institut.com/wp-content/uploads/2023/02/Untitled-design-5.jpg 800 800 Dipl. Ing. Wolfgang Rudloff https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dipl. Ing. Wolfgang Rudloff2023-02-18 17:15:382024-10-29 07:59:27EudraLex Vol. 4 Part IV: One for all?
GMP

The new ANNEX 1 02/2020

ESSAY No. 1 – Acceptance criteria for germ count monitoring in cleanrooms

One of the significant revisions in the draft of the new Annex 1 is the change in the limitation of the bacterial count in cleanroom class “A”. Whereas the previous requirement was that a maximum value of “< 1” was permitted in the core zone of aseptic production, the limit is now set to “no growth”, i.e. “0” CFU/sampling.

Sampling point

This will be a challenge in the future because, in contrast to the new requirement, the current value is an average value per sampling point (air bacteria count, sedimentation plate, contact plate)1) , which means that the number of 1 bacteria can theoretically be exceeded in a sample. According to general GMP understanding, the new requirement implies that the occurrence of a germ immediately leads to an investigation as part of the company’s own deviation management, whereby the cause of the origin of the germ should be found with the greatest possible probability.

Requirement in the new Annex 1

If the requirement in the new Annex 1 is included in the ongoing discussion that in future it should be possible to fully monitor the cleanroom from outside, i.e. outside the A/B zone (suitable windows or camera systems are specifically recommended), this presents a new challenge. In FDA inspections, for example, it is already expected that monitoring activities (quality oversight) will be specifically incorporated into the evaluation of microbial findings in order to establish the greatest possible correlation between the sample train carried out and the event that took place.

For the pharmaceutical manufacturer

In the interpretation of the new Annex 1, this means for the pharmaceutical manufacturer: establishment of documented monitoring of the cleanroom with chronological allocation of sampling/monitoring and events that actually took place in the cleanroom. An exciting task!

Source: 1) ZLG Aide memoire “Monitoring of sterile manufacturers”

Read our entire blog: https://experts-institut.de/newsroom/
And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

18. February 2023/0 Comments/by Dipl. Ing. Wolfgang Rudloff
https://experts-institut.com/wp-content/uploads/2023/02/Untitled-design-5.jpg 800 800 Dipl. Ing. Wolfgang Rudloff https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dipl. Ing. Wolfgang Rudloff2023-02-18 17:13:092024-10-29 07:59:21The new ANNEX 1 02/2020
GMP

GMP reagent management: Many unspoken rules?

So inconspicuous and yet so important, especially from today’s perspective: Section 6.19 of Chapter 6 of the EU GMP guidelines once again significantly increased the effort required to carry out analytical tests:

6.19 Special attention should be given to the quality of laboratory reagents, solutions, glassware, reference standards and culture media. They should be prepared and controlled in accordance with written procedures. The level of controls should be commensurate to their use and to the available stability data.

Miniature manufacturing instructions

If strictly interpreted, this means that a miniature manufacturing instruction and therefore also a specification should be created for each affected article – and of course all of this should be integrated into the usual document control system. No, this has not yet been an explicit requirement to this extent, even if it was tacitly expected in some inspections.

But that’s not all: in order to determine whether and how often, for example, a reagent itself must be tested analytically, stability data must now be used(!) – in a strictly literal interpretation.

Pharmacopoeia descriptions

There are plenty of unanswered questions: Can pharmacopoeia descriptions (if available) replace written manufacturing instructions for reagents? Do expiry dates or re-test data from reagent suppliers also count as stability data in the broadest sense (and this is still not clear)? If I change the manufacturer of an initial reagent, do I have to document everything via a change control procedure, i.e. is this a ‘significant’ change?

No footnotes, no Q&A document from the EMA – until now. However, the consequence of non-compliance with section 6.19 is clear: in extreme cases, analysis results may be called into question and retesting of already marketed products may be necessary as a follow-up measure. Where results were included in the assessment of critical incidents (e.g. OOS events), a reassessment may also be appropriate.

Our recommendation: The legislator has obviously deliberately made long-standing unspoken requirements much clearer. If your lab has any gaps here, don’t put it off, but make an action plan now to fix it! Definitely better than only reacting when the child has fallen into the (GMP inspection) well…

Read our entire blog: https://experts-institut.de/newsroom/
And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

18. February 2023/0 Comments/by Dr. rer. nat. Dietmar Gross
https://experts-institut.com/wp-content/uploads/2023/02/Blogbeitrag-Reagenzien-980x550-1.webp 550 980 Dr. rer. nat. Dietmar Gross https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dr. rer. nat. Dietmar Gross2023-02-18 17:10:092024-10-29 07:59:21GMP reagent management: Many unspoken rules?
GMP, GXP

The GMP Management Review

The GMP Management Review: A highly underestimated instrument of quality assurance

The GMP Management Review: A highly underestimated instrument of quality assurance

The management review is not a new instrument in the GMP quality system; it is also a topic within the latest EU GDP Guidance. Nevertheless: in reality, many GMP companies still do not really know how to deal with this topic – the implementation of the management review is completely lacking in some places. Where does that come from…?

Quality system ICHQ10

It is often not clear to the management and senior management of a GMP company how this requirement for a management review fits into the existing quality system, let alone what the background and purpose of the requirement is. The answer is described in the Guidance on the Pharmaceutical Quality System ICHQ10 – as part of the EU GMP Guidance (Part III Q10), every company should be familiar with this document for its own benefit.

The lack of establishment of the management review

However, the lack of establishment of the management review is not just another item on the list of inspection deficiencies – unfortunately, it is much more serious: for many companies, the management review is part of an actual reorganization of the quality system – in accordance with ICHQ10.

GMP guidelines

Gone are the days when anyone could set up a quality system as they saw fit based on the chapters of the GMP guidelines – a collection of SOPs and processes from the guidelines that were linked together as best they could to form a quality system. Anyone who has not yet realized that ICHQ10 must be the leading principle – the big bracket around the pharmaceutical quality system of a GMP company – has some catching up to do.

ICHQ10

Does this mean having to completely rebuild a quality system? In most cases, adaptation to ICHQ10 should be feasible with manageable effort. However, anyone who has not taken ‘quality management’ in the GMP guidelines seriously for many years – i.e. has seen it more as a formality than an effective management tool – will now have to invest in order not to completely miss the boat when it comes to the GMP compliance required today. And that’s right: this applies not only to the developers of new drugs and their legacy products, but also to manufacturers of generics.

Conclusion

The ray of hope: The management review according to ICHQ10 is not just a manageable hurdle. In particular, the mandatory involvement of senior management means that this is the best opportunity to date to overcome the long-standing and well-known shortcomings of the in-house quality system.

Read our entire blog: https://experts-institut.de/newsroom/
And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

18. February 2023/0 Comments/by Dr. rer. nat. Dietmar Gross
https://experts-institut.com/wp-content/uploads/2023/02/Untitled-design-5.jpg 800 800 Dr. rer. nat. Dietmar Gross https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dr. rer. nat. Dietmar Gross2023-02-18 17:08:292024-10-29 07:59:21The GMP Management Review
GMP, GXP

Media systems – new chapter in Annex 1

Media systems in Annex 1: Vacuum and cooling systems

One of the new chapters in Annex 1 deals with media systems. In addition to requirements for the design and operation of water systems, vacuum and cooling systems are also listed for the first time. Among other things, the new Annex 1 covers the requirement:

“6.23 There should be periodic cleaning/disinfection for both vacuum and cooling systems.”

Condensation phenomena

My comment: This requirement can be misunderstood. This does not mean, for example, that the piping system of the coolant should be cleaned / disinfected (as the first requests for comments have already been received by gmp-experts), which will be difficult as a purely technical system. Rather, this refers to the areas of installations where condensation can lead to localized and permanent moisture formation and thus the risk of germ formation and even biofilm formation.

Regular checks

What should you do? Regular monitoring means integrating these points into routine hygiene monitoring and regularly cleaning and disinfecting the affected areas, e.g. in the refrigerator, but also in the cooling register of a ventilation system. For the latter, the application of VDI 6022 Sheet 3, for example, would be highly recommended. A very good basis for a suitable hygiene plan is provided here in the form of a directly implementable checklist.

Cleaning / disinfection of vacuum systems

The cleaning / disinfection of vacuum systems primarily refers to all systems that are used to remove loads (heat, vapors, moisture, particles) from the environment of the product / process (generally referred to as source exhaust air systems). These can be classic extraction systems on workbenches, vacuum cleaners or permanently connected central extraction systems on process plants (e.g. vapor extraction systems on washing machines).

Pipes / fittings and filters

In any case, cleaning / disinfection in relation to the corresponding clean room zone in which the system is located includes the removal of all contaminants from pipes / fittings and filters that could return to the process / product in the opposite direction to the suction direction during operation.

Requirement from Annex 1

Conclusion of this new requirement from Annex 1, which deals with media systems: A corresponding maintenance / cleaning plan and integration into routine monitoring as a GMP routine is the necessary basis for this and should be included in the company’s hygiene system as an important part of the Contamination Control Strategy (CCS).

Read our entire blog: https://experts-institut.de/newsroom/
And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

18. February 2023/0 Comments/by Dipl. Ing. Wolfgang Rudloff
https://experts-institut.com/wp-content/uploads/2023/02/Medien.webp 504 784 Dipl. Ing. Wolfgang Rudloff https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dipl. Ing. Wolfgang Rudloff2023-02-18 17:06:092024-10-29 07:59:27Media systems – new chapter in Annex 1
GMP

Chapter 6 in the new Annex 1: Supply and media systems

News from Annex 1:

A very interesting statement comes from Annex 1, which in the opinion of gmp-experts should be treated with caution and above all with good GMP expertise:

WFI systems

The new Annex 1 is listed under Chapter 6 – Supply and media systems in subsection 6.15:

“WFI systems should include the use of continuous monitoring systems such as Total Organic Carbon (TOC) and conductivity, as these can give a better indication of biofilm formation that individual samples would not always detect. The placement of sensors should be based on qualification.” (Translation from English by gmp-experts)

Distribution system

To this end:

If a TOC measuring device determines that there is a biofilm in the distribution system, all other GMP systems from the planning, installation, qualification, operating mode and monitoring of ultrapure water systems carried out under the keyword “hygienic design” have categorically failed.

TOC meter

If there is an increase in the values on the TOC device, there must be an extremely high (continuous) bacterial load in the distribution system. In order to detect a ppb of TOC content in the water, a much higher bacterial load in the water is required than the specification requirements according to Pharm.-Eur. allow. If, on the other hand, a single biofilm floc were to find its way into the minimum volume flow of a TOC measurement, this would have to be described as an extremely high random factor.

Biofilms are generally very stationary systems that are more likely to be found in the regions of a water system where things tend to be calm, i.e. without much turbulence. This is therefore more likely to be found in the area of valves (if they are not used / decontaminated for a long time), in narrow gaps where the capillary force with high suction pressure (approx. 0.3 bar at 10µm gap size) allows water to enter, for example, tri-clamp connections or the clamping area of membranes on valves, where a biofilm can form very locally and become firmly established in the long term after the appearance of a germ.

GMP conformity for ultrapure water systems

In principle, GMP conformity for ultrapure water systems is subject to the conditions of a suitable design (hygienic design) and operating mode (production / decontamination) in conjunction with comprehensive, risk-based monitoring. This is the only way to ensure that biofilms can be avoided, eliminated and, above all, detected.

The TOC measuring device detects the total content of organic carbons, which can have many causes, e.g. the presence ofCO2 as a non-condensable gas. Therefore indispensable measuring principle, but not suitable for the intention of Annex 1.

News from Annex 1 – Conclusion

For further discussion of the topic, please refer to the detailed explanations EMA/INS/GMP/443117/2017GMP/GDP Inspectors Working Group: Questionsandanswersonproductionofwaterforinjectionbynon-distillationmethods-reverseosmosisandbiofilmsandcontrolstrategies

Read our entire blog: https://experts-institut.de/newsroom/
And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

18. February 2023/0 Comments/by Dipl. Ing. Wolfgang Rudloff
https://experts-institut.com/wp-content/uploads/2023/02/Fotolia_2970408_S.webp 601 799 Dipl. Ing. Wolfgang Rudloff https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dipl. Ing. Wolfgang Rudloff2023-02-18 17:03:532024-10-29 07:59:27Chapter 6 in the new Annex 1: Supply and media systems
GMP, GXP

Process validation

Process stability – process capability – controlled state –
Important terms that should not be missing in any current process validation
!

Guidelines for process validation

In the current guidelines on process validation (FDA Guidance, Annex 15, Aide memoire 07122901) as well as in more and more inspection reports, there is a requirement for proof of process stability, process capability and the continuation of the controlled state. What is meant by this?

A stable process is a process that predictably delivers products of comparable quality batch after batch. This state can also be referred to as a “controlled process” or a “process under (statistical) control”.

However, process stability does not automatically mean that the process also delivers a product that conforms to specifications. A stable process can also predictably deliver products that are not of the desired quality.

Process stability

Fig. 2: Stable process that violates the specification limits

Therefore, in addition to the term process stability, the guidelines also include the requirement for appropriate process capability. The calculation of the process capability in the form of the process capability index (Ppk or Cpk) sets the scatter of the results and the position of the mean value in relation to the specification limits. High process capability means that the results are so far away from the specification limits that it is very unlikely that OOS results will occur in the batch.

If a process is stable and has good process capability, a product is manufactured that is firstly comparable with the previously produced batches (process stability) and secondly lies safely within the specification limits (process capability).

Process capability

However, the terms process stability and process capability always refer only to a single product characteristic, e.g. the content of the medicinal product, and not, as the terms imply, to the entire process. It is therefore quite possible that a process delivers tablets with reproducible, specification-compliant content, but that these show completely different active ingredient releases from batch to batch.

Product features

Accordingly, it is essential to first identify all critical product features that need to be assessed as part of process validation in a risk-based manner and then, in a second step, to check whether the process is stable and capable with regard to all critical product features.

Read our entire blog: https://experts-institut.de/newsroom/
And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

18. February 2023/0 Comments/by Dipl. oec. troph. Christian Reinfelder
https://experts-institut.com/wp-content/uploads/2023/02/Fotolia_48823999_S-Prozessvalidierung.webp 600 800 Dipl. oec. troph. Christian Reinfelder https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dipl. oec. troph. Christian Reinfelder2023-02-18 17:01:432024-10-29 07:59:27Process validation
Page 3 of 41234
Recent
  • Business Continuity
    Business continuity management: How companies strategically...4 weeks 
  • Continuous Manufacturing
    Continuous manufacturing: future trend in the pharmaceutical...2 months 
  • Qualitätsmanagement
    How to create an effective quality management system (QMS)...31. July 2025 - 10:39
  • Informationssicherheit
    ISMS 2024: What companies need to know now about NIS2, DORA,...3. July 2025 - 12:32
Popular
  • Cultures in Audits & Inspections
    Crossing Cultures in Audits and Inspections30. July 2024 - 9:14
  • Cultures in Audits & Inspections
    Crossing Cultures in Audits and Inspections1. August 2024 - 9:38
  • English
    Quality Management Maturity: The Importance of Good English...22. August 2024 - 12:43
  • VSME-Standard für KMU
    Combining sustainability and success: The new VSME standard...4. September 2024 - 12:06

Tags

AI AI Annex Annex 11 Artificial Intelligence Audit audits Business Continuity Management Cannabis Certification Clean room Computerized systems Continuous Manufacturing CRA Cultures Cytostatics Data Integrity DORA Draft Germ count Germ count monitoring GMP GXP Health insurance Information security inspections ISMS ISO/IEC 42001 ISO 9001 ISO 27001 ISO standard Laboratory Machine Learning NIS-2 NIS2 Pharmacy QMS Quality management system Reagents Regulations Retaxation Sustainability Transformation

Kategorien

  • Business Solutions
  • GMP
  • GXP
  • News
  • Retaxation
  • Sustainability
  • Uncategorized

Archiv

  • October 2025 (1)
  • September 2025 (1)
  • July 2025 (2)
  • March 2025 (1)
  • January 2025 (1)
  • December 2024 (1)
  • November 2024 (1)
  • October 2024 (3)
  • September 2024 (2)
  • August 2024 (2)
  • July 2024 (2)
  • May 2024 (1)
  • April 2024 (2)
  • March 2024 (2)
  • February 2023 (10)

Webpräsenz der Allianz für Cyber- Sicherheit
kununu widget

Business Solutions

  • Digitization
  • Sustainability
  • Management systems
  • Project management
  • Strategy & Performance
  • Transformation & Leadership

GMP / GXP Consulting

  • GMP Consulting
  • GMP audits & inspections
  • GMP/GDP training courses
  • GMP/pharmaceutical engineering
  • Continuous Manufacturing

EI Academy

  • GMP / GxP
  • Academy
  • Live events
  • On-demand webinar

New town

Experts Institut Beratungs GmbH
Weinstraße 85

D-67434 Neustadt a. d. Weinstraße

Phone: +49 (0)6321 969210
E-mail: info@expertsinstitut.de

Fax: +49 (0)6321 9692199

Bamberg

Experts Institut Beratungs GmbH
Untere Sandstraße 53

D-96047 Bamberg

Phone: +49 (0)951 51939330
E-mail: info@expertsinstitut.de

St. Gilgen (Austria)

Experts Institut Beratungs GmbH
Helenenstraße 16

A-5340 St. Gilgen, Austria

Tel.: +43 (0)6227 21068
E-Mail: info@expertsinstitut.de

  • Link to LinkedIn
  • Link to Xing

© 2024 Experts Institut Beratungs GmbH
  • Imprint
  • Data protection
  • AGBs
  • Cookie Directive (EU)
Scroll to top Scroll to top Scroll to top